Know Labs to Present Clinical Research at the 2024 American Physiology Summit

Rhea-AI Summary

Know Labs, Inc. (KNW) has been selected for an abstract poster presentation at the American Physiological Society (APS) Summit, showcasing significant progress in non-invasive blood glucose monitoring technology. The company's proprietary radiofrequency (RF) dielectric sensor has shown improved accuracy in measuring blood glucose, with recent clinical studies demonstrating stability, repeatability, and accuracy of its non-invasive continuous blood glucose monitor. Know Labs aims for FDA clearance and plans to deploy its wearable CGM in large-scale clinical trials to determine real-world applicability.

The Company demonstrates significant progress since presenting at last year’s Summit.

SEATTLE--(BUSINESS WIRE)-- Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it has been selected for an abstract poster presentation at the American Physiological Society (APS) Summit in Long Beach, California on April 4-7, 2024.

The Company will present results titled, “Non-Invasive Blood Glucose Monitoring Using a Radiofrequency Sensor and a Machine Learning Model.” These results demonstrated that novel data preprocessing techniques, continued algorithm refinement and more high-resolution data improved the accuracy for Know Labs’ proprietary radiofrequency (RF) dielectric sensor in measuring blood glucose using a popular CGM as a comparative reference. These results were first published last year.

At the previous APS Summit, Know Labs presented results from its peer-reviewed, proof-of-principle study conducted in collaboration with Mayo Clinic, which assessed the accuracy of its RF dielectric sensor in identifying different analytes in vitro, proving a 100% accuracy rate in these tests. Since then, Know Labs has published several clinical studies demonstrating the stability, repeatability, and accuracy of its non-invasive continuous blood glucose monitor.

Most recently, Know Labs announced interim results from its first clinical research protocol involving people with diabetes, using venous blood as a comparative reference and a machine learning model trained on data collected in a lab setting, which resulted in an overall MARD of 11.1%. Compared to previous studies, in which most of the data collected was within the normoglycemic range and glucose values from a popular CGM were used as comparative reference, this study significantly increased the number of data points within the hyperglycemic range and therefore further validated the medical application of the Company’s proprietary sensor.

During 2024, as the Company continues on the path toward FDA clearance, Know Labs will deploy the KnowU™, its wearable, non-invasive continuous glucose monitor (CGM), in large-scale, external clinical trials to determine real-world applicability, specifically the technology’s performance throughout continuous wear, on different locations on the body, and within more expansive glycemic ranges and diverse populations. To stay updated on the latest results, visit www.knowlabs.co/research-and-development.

About Know Labs, Inc.
Know Labs, Inc. is a public company whose shares trade on the NYSE American Exchange under the stock symbol “KNW.” The Company’s platform technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The technology can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent-pending technology makes it possible to effectively identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The first application of the technology will be in a product marketed as a non-invasive glucose monitor. The device will provide the user with accessible and affordable real-time information on blood glucose levels. This product will require U.S. Food and Drug Administration clearance prior to its introduction to the market.

Safe Harbor Statement
This release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy; and (iv) performance of products. You can identify these statements by the use of the words “may,” “will,” “could,” “should,” “would,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” “likely,” “forecast,” “probable,” “potential,” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. These risks and uncertainties also include such additional risk factors as are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended September 30, 2023, Forms 10-Q and 8-K, and in other filings we make with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations section of our website at www.knowlabs.co. The Company cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240405620925/en/

For Know Labs Media Inquiries Contact:

Matter Health

Abby Mayo

Knowlabs@matternow.com

Ph. (617) 272-0592

Know Labs, Inc. Contact:

Jordyn Hujar

jordyn@knowlabs.co

Ph. (206) 629-6414

Source: Know Labs, Inc.

FAQ

What technology is Know Labs developing?

Know Labs is an emerging developer of non-invasive medical diagnostic technology, specifically focusing on non-invasive blood glucose monitoring.

Where will Know Labs present its results?

Know Labs will present its results at the American Physiological Society (APS) Summit in Long Beach, California on April 4-7, 2024.

What is the title of the results being presented by Know Labs?

The results being presented by Know Labs are titled 'Non-Invasive Blood Glucose Monitoring Using a Radiofrequency Sensor and a Machine Learning Model.'

What was the accuracy rate of Know Labs' RF dielectric sensor in identifying different analytes in vitro?

Know Labs' RF dielectric sensor demonstrated a 100% accuracy rate in identifying different analytes in vitro during its proof-of-principle study conducted in collaboration with Mayo Clinic.

What was the overall MARD in Know Labs' first clinical research protocol involving people with diabetes?

The overall MARD in Know Labs' first clinical research protocol involving people with diabetes was 11.1%.